Efficacy of uncovered self-expandable metallic stent for colorectal obstruction by extracolonic malignancy

Table 5 Baseline characteristics according to stent occlusion, n (%)

	Patent stent group (n = 41, 71.9%)	Stent occlusion group (n = 16, 28.1%)	P value
Age (yr, mean ± SD)	56.2 ± 12.4	58.3 ± 7.9	0.660
Male	15 (36.6)	8 (50.0)	0.354
Primary malignancy			0.231
Upper abdominal cancer	28 (68.3)	14 (87.5)
Lower abdominal cancer	11 (26.8)	1 (6.3)
Extra abdominal cancer	2 (4.9)	1 (6.3)
Obstruction site			0.198
Left colon	28 (68.3)	8 (50.0)
Sigmoid colon	13 (31.7)	8 (50.0)
Obstruction			1.000
Partial	4 (9.8)	2 (12.5)
Near total	37 (90.2)	14 (87.5)
Peritoneal carcinomatosis	31 (75.6)	11 (68.8)	0.739
Previous chemotherapy	35 (85.4)	14 (87.5)	1.000
Previous radiotherapy	6 (14.6)	3 (18.8)	0.700
Stent length ≤ 10 cm	21 (51.2)	15 (93.8)	0.003

Upper abdominal cancer: Gastric cancer and pancreaticobiliary cancer; Lower abdominal cancer: Ovarian cancer, uterine cancer, and bladder cancer; Left colon: From the rectum to descending colon; Right colon: From the splenic flexure to ascending colon.